enGene (ENGN) Stock Price, News & Analysis

Company Overview

enGene, Inc. is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages. Each EDV is surface‐decorated with bispecific antibodies designed to bind specific tumor antigens, enabling selective accumulation in malignant tissues. The platform supports a range of payloads—from chemotherapeutic agents to nucleic acid–based molecules—providing versatility in addressing diverse tumor profiles.

Headquartered in San Diego, California, enGene collaborates with leading academic and research institutions to propel its pipeline forward. The company is overseen by a management team with deep expertise in gene and cell therapy development, drug delivery systems, and oncology research, positioning enGene to tackle the complex challenges inherent in targeted cancer therapy.

Key Stats

• Today's Range: $5.52 to $6.54
• 50-Day Range: $3.31 to $6.29
• 52-Week Range: $2.65 to $11.00
• Volume: 86,055 shs
• Average Volume: 213,327 shs
• Market Capitalization: $291.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Buy

enGene Stock Analysis - MarketRank™

enGene scored higher than 57% of companies evaluated by MarketBeat, and ranked 566th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

enGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

enGene has a consensus price target of $21.00, representing about 267.8% upside from its current price of $5.71.

Amount of Analyst Coverage

enGene has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for enGene are expected to decrease in the coming year, from ($1.56) to ($1.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of enGene is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of enGene is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

enGene has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.07% of the float of enGene has been sold short.

Short Interest Ratio / Days to Cover

enGene has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in enGene has recently increased by 206.52%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

enGene does not currently pay a dividend.

Dividend Growth

enGene does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.07% of the float of enGene has been sold short.

Short Interest Ratio / Days to Cover

enGene has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in enGene has recently increased by 206.52%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.30

News Sentiment

enGene has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 30 news articles for enGene this week, compared to 8 articles on an average week.

Search Interest

1 people have searched for ENGN on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added enGene to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, enGene insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.40% of the stock of enGene is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.16% of the stock of enGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ENGN Stock Analysis - Frequently Asked Questions

How have ENGN shares performed this year?

enGene's stock was trading at $6.65 at the beginning of 2025. Since then, ENGN stock has decreased by 14.1% and is now trading at $5.71.

How were enGene's earnings last quarter?

enGene Holdings Inc. (NASDAQ:ENGN) announced its quarterly earnings data on Thursday, September, 11th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.06.

Who are enGene's major shareholders?

Top institutional investors of enGene include Franklin Resources Inc. (2.03%), Adage Capital Partners GP L.L.C. (1.96%), Orbimed Advisors LLC (1.33%) and Affinity Asset Advisors LLC (0.15%). Insiders that own company stock include De Solidarite Des Travai Fonds and Growth Opportunities F Forbion.
View institutional ownership trends.

How do I buy shares of enGene?

Shares of ENGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of enGene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that enGene investors own include PayPal (PYPL), United Microelectronics (UMC), XPeng (XPEV), Adverum Biotechnologies (ADVM), AngioDynamics (ANGO), APi Group (APG) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Last Earnings: 9/11/2025
• Today: 9/14/2025
• Fiscal Year End: 10/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENGN
• Previous Symbol: NASDAQ:ENGN
• CIK: 1980845
• Web: www.engene.com
• Phone: 302-273-0765
• Fax: N/A
• Employees: 31
• Year Founded: N/A

Price Target and Rating

• Average Price Target for enGene: $21.00
• High Price Target: $30.00
• Low Price Target: $7.00
• Potential Upside/Downside: +267.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.14 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -37.90%
• Return on Assets: -32.90%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 12.66
• Quick Ratio: 12.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.35 per share
• Price / Book: 1.07

Miscellaneous

• Outstanding Shares: 51,105,000
• Free Float: 45,790,000
• Market Cap: $291.81 million
• Optionable: N/A
• Beta: -0.39